2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
6
Neoplasms
6
Pulmonary Embolism
5
Thromboembolism
3
Lung Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Irinotecan
8
Bevacizumab
8
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
Capecitabine
4
Drug Therapy
3
Cetuximab
3
5,10-methylenetetrahydrofolic acid
3
Radiotherapy
2
Levoleucovorin
2
Folfox protocol
2
Colonoscopy
2
Bisacodyl
2
Aspirin
2
Artesunate
2
trametinib
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
nazartinib
1
napabucasin
1
lutetium Lu 177 dotatate
1
guadecitabine
1
encorafenib
1
copper dotatate CU-64
1
canakinumab
1
camrelizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Intestinal Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled